We expect 4Q13 health services demand growth (y/y, nominal) of 3.3%, the product of 2.2% growth in unit demand and 1.1% growth in nominal pricing (Exhibit 1). Our nominal pricing…
NVS’ R&D spending as a percent of sales is on par with its peer group (Exhibit 1), as are its economic returns to R&D spending (yr10 operating income / yr1…
On October 20, the Wall Street Journal published an interview with LLY’s CEO, addressing the question of whether LLY’s relatively high R&D spending versus peers (Exhibit 1) is warranted. With…
As of September 2013, we expected 3Q13 health services demand growth (y/y, nominal) of 3.5%, the product of 2.1% growth in unit demand and 1.4% growth in nominal pricing (Exhibit…
Background At current (branded, single-source) prices, erythropoiesis stimulating agents (ESA’s) represent about one-quarter of care costs for Medicare dialysis patients, and 11 percent of care costs for commercially-insured patients The…
Summary and Conclusions Despite the ACA’s razor-thin margin of passage and ideologically narrow base of support, more Americans want to see the Act implemented than to see it dismantled, or…
Price : Quantity relationships in the employer sponsored (ESI) market To estimate price elasticity of demand for health insurance in the employer sponsored (ESI) market, we define the price of…
We expect 3Q13 health services demand growth (y/y, nominal) of 3.5%, the product of 2.1% growth in unit demand and 1.4% growth in nominal pricing (Exhibit 1). Our nominal pricing…
Background State Medicaid programs use a variety of drug pricing benchmarks to determine how much a retail pharmacy is paid when a multi-source (generic, essentially) prescription is dispensed to a…
Premise and rationale behind the ‘Hidden Pipeline’ valuation method Share prices of drug and biotech stocks arguably can be broken down into two major components: the capital markets’ estimates of…